Ex­clu­sive: Fol­low­ing a se­vere set­back, Bridge­Bio brings out the bud­get axe to chop staff but keeps qui­et on the num­bers

Three months af­ter Bridge­Bio’s TTR amy­loi­do­sis can­di­date suf­fered a ma­jor — and ac­cord­ing to CEO Neil Ku­mar, “baf­fling” — Phase III fail that wiped out $4 bil­lion in mar­ket cap, End­points News has learned that the com­pa­ny is swing­ing the bud­get axe, all while ly­ing  low as best it can dur­ing the re­struc­tur­ing.

Af­ter re­ceiv­ing a call and track­ing so­cial me­dia posts re­gard­ing a num­ber of lay­offs at Bridge­Bio, Ku­mar con­firmed that the com­pa­ny has made cuts with­out spec­i­fy­ing just how many.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER